Literature DB >> 2539101

Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1.

M Ross1, G L Francis, L Szabo, J C Wallace, F J Ballard.   

Abstract

(1) Many cell types secrete insulin-like growth factor (IGF)-binding proteins that can be expected to sequester free IGF and modify the biological activities of the growth factors. (2) A binding protein purified from bovine kidney (MDBK) cells potently inhibited the ability of IGF-2 to stimulate DNA synthesis or protein accumulation as well as to reduce rates of protein breakdown in chick embryo fibroblasts. The binding protein did not influence the biological activities of des-(1-3)-IGF-1, while effects on IGF-1 were intermediate. Since the chick embryo fibroblasts contain only the type 1 IGF receptor, the MDBK-cell binding protein must have reduced the accessibility of IGF-2 and IGF-1 to that receptor. Binding to the type 2 receptor on L6 myoblasts was also inhibited. (3) Inhibiting effects on both protein breakdown responsiveness to IGF and IGF binding to cell receptors were also observed with human amniotic fluid binding protein, although here IGF-1 and IGF-2 were equipotent. These results contrast with stimulatory responses on different IGF-1 actions of the same binding protein reported previously [Elgin, Busby & Clemmons (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 3254-3258]. (4) The biological potencies of IGF-1, IGF-2 and des-(1-3)-IGF-1 correlate inversely with their binding to proteins released into the medium by cells, so that the enhanced potency of des-(1-3)-IGF-1 is a consequence of it not binding to purified binding proteins or those released by cultured cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539101      PMCID: PMC1138350          DOI: 10.1042/bj2580267

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  Fetal sheep serum contains a high molecular weight insulin-like growth factor (IGF) binding protein that is acid stable and specific for IGF-II.

Authors:  A W Hey; C A Browne; G D Thorburn
Journal:  Endocrinology       Date:  1987-12       Impact factor: 4.736

2.  Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding.

Authors:  F J Ballard; G L Francis; M Ross; C J Bagley; B May; J C Wallace
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

3.  Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively.

Authors:  F J Ballard; M Ross; F M Upton; G L Francis
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

4.  Effects of local cell concentrations upon the growth of chick embryo cells in tissue culture.

Authors:  A Rein; H Rubin
Journal:  Exp Cell Res       Date:  1968-03       Impact factor: 3.905

5.  Interactions of insulin-like growth factors I and II and multiplication-stimulating activity with receptors and serum carrier proteins.

Authors:  M M Rechler; J Zapf; S P Nissley; E R Froesch; A C Moses; J M Podskalny; E E Schilling; R E Humbel
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

6.  C-terminal bombesin sequence requirements for binding and effects on protein synthesis in Swiss 3T3 cells.

Authors:  S E Gargosky; J C Wallace; F M Upton; F J Ballard
Journal:  Biochem J       Date:  1987-10-15       Impact factor: 3.857

7.  Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein.

Authors:  D J Knauer; G L Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

8.  Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells.

Authors:  O Ritvos; T Ranta; J Jalkanen; A M Suikkari; R Voutilainen; H Bohn; E M Rutanen
Journal:  Endocrinology       Date:  1988-05       Impact factor: 4.736

9.  The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding.

Authors:  L Szabo; D G Mottershead; F J Ballard; J C Wallace
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

10.  Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form.

Authors:  G L Francis; F M Upton; F J Ballard; K A McNeil; J C Wallace
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

View more
  23 in total

1.  Granulosa cell-derived insulin-like growth factor (IGF) binding proteins are inhibitory to IGF-I hormonal action. Evidence derived from the use of a truncated IGF-I analogue.

Authors:  E Y Adashi; C E Resnick; E Ricciarelli; A Hurwitz; E Kokia; C Tedeschi; L Botero; E R Hernandez; R G Rosenfeld; C Carlsson-Skwirut
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

2.  Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I.

Authors:  R Hirschberg
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities.

Authors:  K E Bornfeldt; R A Gidlöf; A Wasteson; M Lake; A Skottner; H J Arnqvist
Journal:  Diabetologia       Date:  1991-05       Impact factor: 10.122

4.  Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation.

Authors:  Makoto Nakasato; Hitoshi Kohsaka; Tetsuya Mizutani; Gen Watanabe; Kazuyoshi Taya; Kentaro Nagaoka
Journal:  Endocrine       Date:  2012-08-17       Impact factor: 3.633

Review 5.  A (selective) history of Australian involvement in cytokine biology.

Authors:  Nicos A Nicola
Journal:  Cytokine Growth Factor Rev       Date:  2013-03-30       Impact factor: 7.638

6.  Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner.

Authors:  T Niikura; Y Hashimoto; T Okamoto; Y Abe; T Yasukawa; M Kawasumi; T Hiraki; Y Kita; K Terashita; K Kouyama; I Nishimoto
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 7.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

8.  Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II.

Authors:  G L Francis; S E Aplin; S J Milner; K A McNeil; F J Ballard; J C Wallace
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

9.  Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Authors:  Y Imai; W H Busby; C E Smith; J B Clarke; A J Garmong; G D Horwitz; C Rees; D R Clemmons
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

10.  Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3.

Authors:  V Hwa; Y Oh; R G Rosenfeld
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.